Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Fourth Quarter and Full Year 2024

Significant Demand for Amtagvi® (Lifileucel) Continues with Total Product Revenue of $73.7M in 4Q24 and$164.1M in FY24, Achieving Upper End of FY24 Guidance Range of $160M-$165M Reaffirming FY25 Total Product Revenue Guidance of $450M-$475M FY25 Cash Burn Anticipated to be Under $300M 2025 Regulatory Approvals for Amtagvi Expected in the UK, EU, and Canada Enrollment Accelerating Across Global Registrational Trials in Frontline Advanced Melanoma and Previously Treated Advanced NSCLC SAN CARLOS, Calif., F ...